HK Stock Market Move | ZYLOXTB (02190) rises more than 6% against the market trend, exceeding annual performance expectations, and accelerates globalization through the acquisition of Germany's Optimed.

ZYLOXTB (02190) rose more than 6% against the market, as of press time, it has risen by 4.81% to 23.1 Hong Kong dollars, with a turnover of 176.069 million Hong Kong dollars. On the news front, ZYLOXTB recently released its annual performance, with annual operating income of 1.057 billion RMB, an increase of 35.1% year-on-year; net profit exceeded 244 million RMB, a substantial increase of 143.7% year-on-year. Zhongjin Securities stated that with the continuous advancement of centralized procurement and the intensifying industry competition, due to the volume increase of new products and operational efficiency improvement, the company still achieved double-digit growth in revenue and profits, better than expected. The bank pointed out that in 2025, the company's overseas business income was 48.65 million RMB, a year-on-year increase of 216%. Currently, the company has 29 products commercialized in 40 countries and regions, covering 7 of the top ten markets globally. The company is continuing its step-by-step acquisition of Germany's Optimed. The bank believes that this transaction is expected to complement the company's overseas brand, channel, manufacturing, and clinical resource capabilities, further driving the company towards becoming a globalized vascular intervention device enterprise.